Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-NOV-2023. These Ordinary Shares will be under lockup for 365 days starting from 3-NOV-2022 to 3-NOV-2023.

Details:
Each of the Pre-IPO Investors have agreed to provide a lock-up undertaking in favor of the Company and the Joint Global Coordinators (for themselves and on behalf of the Underwriters). Pursuant to the Lock-up Undertakings (which are in largely similar form, except certain special circumstances), each of the Pre-IPO Investors agrees to a lock-up in respect of the Shares it held upon Listing during the period commencing from the date of the respective Lock-up Undertakings and ending on the date which is 180 days from the Listing Date, subject to customary exceptions.

Pursuant to Rule 10.07 of the Listing Rules, each of the Controlling Shareholders has undertaken to the Stock Exchange and the Company that, they will not and will procure that the relevant registered holder(s) will not without the prior written consent of the Stock Exchange or unless otherwise in compliance with the applicable requirement of the Listing Rules: (a) in the period commencing on the date by reference to which disclosure of its shareholdings in the Company is made in this prospectus and ending on the date which is six months from the Listing Date (the ?First Six-Month Period?), either directly or indirectly, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the securities of the Company in respect of which it is shown by this prospectus to be the beneficial owner; and (b) in the period of six months from the expiry of the First Six-Month Period, either directly or indirectly, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the securities referred to in paragraph (a) above if, immediately following such disposal or upon the exercise or enforcement of such options, rights, interests or encumbrances, it would cease to be a controlling shareholder of the Company.